Novo Integrated Sciences (NVOS) 10-Q22 Jan 242024 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Nov. 30, 2023	Jan. 22, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Nov. 30, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--08-31
Entity File Number	001-40089
Entity Registrant Name	Novo Integrated Sciences, Inc.
Entity Central Index Key	0001138978
Entity Tax Identification Number	59-3691650
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	11120 NE 2nd Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(206)
Local Phone Number	617-9797
Title of 12(b) Security	Common Stock
Trading Symbol	NVOS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		17,748,320

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Current Assets:
Cash and cash equivalents	$ 1,640,007	$ 416,323
Accounts receivable, net	2,636,174	1,467,028
Inventory, net	1,270,835	1,106,983
Other receivables	1,047,742	1,051,584
Prepaid expenses and other current assets	213,812	346,171
Total current assets	6,808,570	4,388,089
Property and equipment, net	5,306,613	5,390,038
Intangible assets, net	15,704,218	16,218,539
Right-of-use assets, net	1,870,204	1,983,898
Goodwill	7,554,779	7,582,483
TOTAL ASSETS	37,244,384	35,563,047
Current Liabilities:
Accounts payable	3,403,634	3,513,842
Accrued expenses	1,300,549	1,233,549
Accrued interest (including amounts to related parties)	480,719	382,666
Government loans and notes payable, current portion	93,488	277,405
Convertible notes payable, net of discount of $3,118,819	1,103,959	558,668
Derivative liability	2,686,260
Contingent liability	52,749	61,767
Debentures, related parties	913,474	916,824
Finance lease liability	8,907	11,744
Operating lease liability, current portion	413,506	415,392
Total current liabilities	10,915,511	7,904,858
Government loans and notes payable, net of current portion	63,777	65,038
Operating lease liability, net of current portion	1,585,667	1,693,577
Deferred tax liability	1,395,381	1,400,499
TOTAL LIABILITIES	13,960,336	11,063,972
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at November 30, 2023 and August 31, 2023, respectively
Common stock; $0.001 par value; 499,000,000 shares authorized; 17,291,192 and 15,759,325 shares issued and outstanding at November 30, 2023 and August 31, 2023, respectively	17,292	15,760
Additional paid-in capital	95,481,354	90,973,316
Common stock to be issued (17,375 and 91,138 shares at November 30, 2023 and August 31, 2023)	44,443	1,217,293
Other comprehensive loss	(246,488)	(357,383)
Accumulated deficit	(71,713,384)	(67,033,041)
Total Novo Integrated Sciences, Inc. stockholders’ equity	23,583,217	24,815,945
Noncontrolling interest	(299,169)	(316,870)
Total stockholders’ equity	23,284,048	24,499,075
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	37,244,384	35,563,047
Related Party [Member]
Current Liabilities:
Due to related parties	$ 458,266	$ 533,001

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Statement of Financial Position [Abstract]
Convertible notes payable net of discount current	$ 3,118,819	$ 3,118,819
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	499,000,000	499,000,000
Common stock, shares issued	17,291,192	15,759,325
Common stock, shares outstanding	17,291,192	15,759,325
Common stock to be issued, shares	17,375	91,138

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Income Statement [Abstract]
Revenues	$ 3,891,218	$ 3,419,280
Cost of revenues	1,947,200	1,679,747
Gross profit	1,944,018	1,739,533
Operating expenses:
Selling expenses	9,586	7,332
General and administrative expenses	5,252,069	3,974,161
Total operating expenses	5,261,655	3,981,493
Loss from operations	(3,317,637)	(2,241,960)
Non-operating income (expense)
Interest income	2,219	2,281
Interest expense	(143,374)	(167,243)
Other expense	(652,174)
Change in fair value of derivative liability	585,529
Amortization of debt discount	(1,075,928)	(1,490,513)
Foreign currency transaction losses	(59,358)	(39,301)
Total non-operating expense	(1,343,086)	(1,694,776)
Loss before income taxes	(4,660,723)	(3,936,736)
Income tax expense
Net loss	(4,660,723)	(3,936,736)
Net income (loss) attributed to noncontrolling interest	19,620	(1,323)
Net loss attributed to Novo Integrated Sciences, Inc.	(4,680,343)	(3,935,413)
Comprehensive loss:
Net loss	(4,660,723)	(3,936,736)
Foreign currency translation gain (loss)	108,976	(420,982)
Comprehensive loss:	$ (4,551,747)	$ (4,357,718)
Weighted average common shares outstanding - basic	16,726,308	3,385,508
Weighted average common shares outstanding - diluted	16,726,308	3,385,508
Net loss per common share - basic	$ (0.28)	$ (1.16)
Net loss per common share - diluted	$ (0.28)	$ (1.16)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock To Be Issued [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total Novo Stockholders Equity [Member]	Noncontrolling Interest [Member]	Total
Balance at Aug. 31, 2022	$ 3,118	$ 66,084,887	$ 9,474,807	$ 560,836	$ (53,818,489)	$ 22,305,159	$ (257,588)	$ 22,047,571
Balance, shares at Aug. 31, 2022	3,118,063
Cashless exercise of warrants	$ 467	$ 1,138,583				$ 1,139,050		$ 1,139,050
Cashless exercise of warrants, shares	467,399
Issuance of common stock to be issued	4	92,362	(92,366)
Issuance of common stock to be issued, shares	3,623
Foreign currency translation loss				$ (417,008)		$ (417,008)	$ (3,974)	$ (420,982)
Net Income (loss)					(3,935,413)	(3,935,413)	(1,323)	(3,936,736)
Units issued for cash, net of offering costs	$ 400	1,794,600				1,795,000		1,795,000
Units issued for cash, net of offering costs, shares	400,000
Fair value of stock options		60,887				60,887		60,887
Balance at Nov. 30, 2022	$ 3,989	69,171,319	9,382,441	143,828	(57,753,902)	20,947,675	(262,885)	20,684,790
Balance, shares at Nov. 30, 2022	3,989,085
Balance at Aug. 31, 2023	$ 15,760	90,973,316	1,217,293	(357,383)	(67,033,041)	24,815,945	(316,870)	24,499,075
Balance, shares at Aug. 31, 2023	15,759,325
Cashless exercise of warrants	$ 246	1,323,152				1,323,398		1,323,398
Cashless exercise of warrants, shares	245,802
Exercise of warrants for cash	$ 240	240,160				240,400		240,400
Exercise of warrants for cash, shares	240,400
Share issuance for convertible debt settlement	$ 520	$ 577,002				$ 577,522		$ 577,522
Share issuance for convertible debt settlement, shares	519,845
Issuance of common stock to be issued	74	1,172,776	(1,172,850)
Issuance of common stock to be issued, shares	73,767
Common stock issued for services	$ 424	$ 1,194,976				$ 1,195,400		$ 1,195,400
Common stock issued for services, shares	424,080
Rounding due to stock split	$ 28	(28)
Rounding due to stock split	27,973
Foreign currency translation loss				110,895		110,895	(1,919)	108,976
Net Income (loss)					(4,680,343)	(4,680,343)	19,620	(4,660,723)
Balance at Nov. 30, 2023	$ 17,292	$ 95,481,354	$ 44,443	$ (246,488)	$ (71,713,384)	$ 23,583,217	$ (299,169)	$ 23,284,048
Balance, shares at Nov. 30, 2023	17,291,192

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Aug. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,660,723)	$ (3,936,736)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	572,404	586,166
Fair value of vested stock options		60,887
Financing costs for debt extension	1,323,398	1,139,050
Common stock issued for services	1,195,400
Operating lease expense	149,877	209,846
Amortization of debt discount	1,075,928	1,490,513
Foreign currency transaction losses	59,358	39,301
Change in fair value of derivative liability	(585,529)
Changes in operating assets and liabilities:
Accounts receivable	(1,168,350)	28,174
Inventory	(166,476)	(157,118)
Prepaid expenses and other current assets	130,584	1,471
Accounts payable	(98,996)	321,961
Accrued expenses	71,214	149,945
Accrued interest	99,430	(9,232)
Operating lease liability	(149,877)	(202,465)
Net cash used in operating activities	(2,152,358)	(278,237)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties	(72,402)	(48,480)
Repayments of notes payable	(183,100)
Repayments of finance leases	(2,779)	(2,763)
Proceeds from issuance of convertible notes	3,314,153
Repayment of convertible notes		(2,777,778)
Proceeds from the sale of units, net of offering costs		1,795,000
Proceeds from exercise of warrants	240,400
Net cash provided by (used in) financing activities	3,296,272	(1,034,021)
Effect of exchange rate changes on cash and cash equivalents	79,770	12,271
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1,223,684	(1,299,987)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	416,323	2,178,687	$ 2,178,687
CASH AND CASH EQUIVALENTS, END OF PERIOD	1,640,007	878,700	$ 416,323
CASH PAID FOR:
Interest	45,321	186,911
Income taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Debt discount recognized on derivative liability	3,071,653	1,390,380
Common stock issued for convertible debt settlement	577,522
Debt discount recognized on convertible note	$ 3,735,414

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
Pay vs Performance Disclosure - USD ($)	Nov. 30, 2023	Nov. 30, 2022
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (4,680,343)	$ (3,935,413)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Nov. 30, 2023
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization and Basis of Prese

Organization and Basis of Presentation	3 Months Ended
Organization and Basis of Presentation	Nov. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation Organization and Line of Business Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries. The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, unique personalized product offerings, and rehabilitative science. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: ● First Pillar – Service Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. ● Second Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home. ● Third Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) Novo Healthnet Limited (“NHL”), (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 1,677,974 85 On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, and not as a business combination, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $ 6,904 Reverse Stock Split On November 7, 2023, the Company effected a 1-for-10 reverse stock split 1-for-10 reverse stock split Basis of Presentation The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations. The financial information contained in this report should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended August 31, 2023, that the Company filed on December 14, 2023. The results of operations for the three months ended November 30, 2023 are not necessarily indicative of the results for the fiscal year ending August 31, 2024. The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”) and the parent company’s functional currency is the United States Dollar (“$” or “USD”); however, the accompanying unaudited condensed consolidated financial statements were translated and presented in USD. Going Concern The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued. The Company has incurred recurring losses from operations, has negative cash flows from operating activities, and has an accumulated deficit as of November 30, 2023. The Company believes that its cash and other available resources may not be sufficient to meet its operating needs and the payment of obligations related to various business acquisitions as they come due within one year after the date the unaudited condensed consolidated financial statements are issued. In an effort to alleviate these conditions, the Company has considered equity and/or debt financing and/or asset monetization. There can be no assurance that funding would be available, or that the terms of such funding would be on favorable terms if available. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stockholders, in the case of equity financing. These conditions, along with the matters noted above, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. While management has developed and is in process to implement plans that management believes could alleviate in the future the substantial doubt that was raised, management concluded at the date of the issuance of the unaudited condensed consolidated financial statements that substantial doubt exists as those plans are not completely within the control of management. These unaudited condensed consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and consolidated balance sheets classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material. Foreign Currency Translation The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction Comprehensive Income Schedule of Foreign Currency Translation, Exchange Rate Used November 30, 2023 November 30, 2022 August 31, 2023 Period end: CAD to USD exchange rate $ 0.7363 $ 0.7403 $ 0.7390 Average period: CAD to USD exchange rate $ 0.7324 $ 0.7414 $ 0.7426

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Nov. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, valuation of derivative liability, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls, including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss. Cash Equivalents For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of November 30, 2023 and August 31, 2023, the allowance for uncollectible accounts receivable was $ 855,116 864,215 Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of November 30, 2023 and August 31, 2023, the Company’s allowance for slow moving or obsolete inventory was $ nil nil Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the three months ended November 30, 2023 and year ended August 31, 2023, the Company wrote off $ nil nil Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5 Leases The Company applies the provisions of ASC Topic 842, Leases Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment no Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its review at November 30, 2023, the Company believes there was no Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. Based on its review at November 30, 2023, the Company believes there was no Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Beginning balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Foreign currency translation adjustment (675 ) (443 ) (783 ) (25,801 ) (2 ) (27,704 ) Balance, November 30, 2023 $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 Ending balance $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of November 30, 2023 and August 31, 2023, respectively, the Company did not identify any financial assets and liabilities required to be presented on the condensed consolidated balance sheet at fair value, except for contingent liability which is carried at fair value using Level 1 inputs and derivative liability which is carried at fair value using Level 3 inputs. Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives. Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery. In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying condensed consolidated balance sheets. Sales returns and allowances were insignificant for the three months ended November 30, 2023 and 2022. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 659,616 1,860,950 3,786,454 17,375 Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented. Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gain of $ 108,976 922,609 Condensed Consolidated Statements of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the condensed consolidated balance sheets. Segment Reporting ASC Topic 280, Segment Reporting two Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying condensed consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Related Party Transactions

Related Party Transactions	3 Months Ended
Related Party Transactions	Nov. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Due to related parties Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At November 30, 2023 and August 31, 2023, the amount due to related parties was $ 458,266 533,001 376,701 nil 6 81,565 13.75 451,137 21,267 6 60,597 13.75

Accounts Receivables, Net

Accounts Receivables, Net	3 Months Ended
Accounts Receivables, Net	Nov. 30, 2023
Receivables [Abstract]
Accounts Receivables, Net	Note 4 – Accounts Receivables, Net Accounts receivables, net at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Accounts Receivable, Net November 30, August 31, 2023 2023 Trade receivables $ 3,412,783 $ 2,223,243 Amounts earned but not billed 78,507 108,000 Accounts receivables gross 3,491,290 2,331,243 Allowance for doubtful accounts (855,116 ) (864,215 ) Accounts receivable, net $ 2,636,174 $ 1,467,028

Inventory

Inventory	3 Months Ended
Inventory	Nov. 30, 2023
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Inventory November 30, August 31, 2023 2023 Raw materials $ 516,811 $ 388,391 Work in process 108,244 81,696 Finished Goods 645,780 636,896 Inventory Gross 1,270,835 1,106,983 Allowance for slow moving and obsolete inventory - - Inventory, net $ 1,270,835 $ 1,106,983

Other Receivables

Other Receivables	3 Months Ended
Other Receivables	Nov. 30, 2023
Receivables [Abstract]
Other Receivables	Note 6 – Other Receivables Other receivables at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Other Receivables November 30, August 31, Advance to corporation; accrues interest at 12 January 31, 2024 $ 73,630 $ 73,900 Advance to corporation; accrues interest at 12 February 1, 2024 532,433 534,386 Advance to corporation; accrues interest at 10 February 1, 2024 441,679 443,298 Total other receivables 1,047,742 1,051,584 Current portion (1,047,742 ) (1,051,584 ) Long-term portion $ - $ -

Property and Equipment

Property and Equipment	3 Months Ended
Property and Equipment	Nov. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment Property and equipment at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Property and Equipment November 30, August 31, 2023 2023 Land $ 441,780 $ 443,400 Building 3,313,350 3,325,500 Leasehold improvements 838,297 841,371 Clinical equipment 1,909,678 1,916,681 Computer equipment 33,381 33,504 Office equipment 44,400 44,502 Furniture and fixtures 38,149 38,289 Property and Equipment gross 6,619,035 6,643,247 Accumulated depreciation (1,312,422 ) (1,253,209 ) Total $ 5,306,613 $ 5,390,038 Depreciation expense for the three months ended November 30, 2023 and 2022 was $ 72,604 60,043 Certain property and equipment have been used to secure notes payable (See Note 10).

Intangible Assets

Intangible Assets	3 Months Ended
Intangible Assets	Nov. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8 – Intangible Assets Intangible assets at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Intangible Assets November 30, August 31, 2023 2023 Land use rights $ 11,573,321 $ 11,573,321 Intellectual property 7,487,410 7,497,746 Customer relationships 2,287,746 2,291,058 Brand names 1,921,375 1,928,421 Finite lived intangible assets, gross 23,269,852 23,290,546 Accumulated amortization (7,565,634 ) (7,072,007 ) Total $ 15,704,218 $ 16,218,539 Amortization expense for the three months ended November 30, 2023 and 2022 was $ 499,800 526,123 Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of intangible Assets Twelve Months Ending November 30, 2024 $ 2,003,586 2025 1,820,324 2026 1,454,624 2027 1,208,004 2028 639,025 Thereafter 8,578,655 Total $ 15,704,218

Accrued Expenses

Accrued Expenses	3 Months Ended
Accrued Expenses	Nov. 30, 2023
Payables and Accruals [Abstract]
Accrued Expenses	Note 9 – Accrued Expenses Accrued expenses at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Accrued Expenses November 30, August 31, 2023 2023 Accrued liabilities $ 1,049,543 $ 961,897 Accrued payroll 215,936 236,218 Unearned revenue 35,070 35,434 Accrued expense $ 1,300,549 $ 1,233,549

Government Loans and Notes Paya

Government Loans and Notes Payable	3 Months Ended
Government Loans and Notes Payable	Nov. 30, 2023
Government Loans And Notes Payable
Government Loans and Notes Payable	Note 10 – Government Loans and Notes Payable Notes payable at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Governmental Loans and Note Payable November 30, August 31, 2023 2023 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program ( A 88,356 88,680 Note payable to the Small Business Administration. The note bears interest at 3.75 190 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 4,000 December 2, 2028 28,589 28,693 Note payable received May 25, 2023, accruing interest at 18 - 73,900 Note payable received May 10, 2023, accruing interest at 15 - 110,850 Total government loans and notes payable 157,265 342,443 Less current portion (93,488 ) (277,405 ) Long-term portion $ 63,777 $ 65,038 (A) The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 58,904 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,452 Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of government Loans and Notes Payable Twelve Months Ending November 30, 2024 $ 93,488 2025 6,470 2026 6,469 2027 6,469 2028 6,469 Thereafter 37,900 Total $ 157,265

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
Convertible Notes Payable	Nov. 30, 2023
Convertible Notes Payable
Convertible Notes Payable	Note 11 – Convertible Notes Payable Novo Integrated On December 14, 2021, Novo Integrated issued two convertible notes payable for a total of $ 16,666,666 8,333,333 5 June 14, 2023 20 In connection with the $16.66m+ convertible notes, the Company issued the note holders warrants to purchase a total of 583,334 20 December 14, 2025 7,680,156 ● Expected life of 4.0 ● Volatility of 275 ● Dividend yield of 0 ● Risk free interest rate of 1.23 The face amount of the $16.66m+ convertible notes of $ 16,666,666 11,409,200 5,257,466 5,257,466 1,666,666 1,140,000 8,064,132 On November 14, 2022, the $16.66m+ convertible notes were amended to provide the holders with conversion rights consisting of a conversion price to the first $ 1,000,000 (i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. derivative liability 1,390,380 ● Expected life of 0.58 ● Volatility of 148.20 ● Dividend yield of 0 ● Risk free interest rate of 4.55 The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible notes. During the year ended August 31, 2023, an aggregate of $ 8,396,666 32,559 8,527,835 1,000,000 1,390,380 nil nil During the year ended August 31, 2023, the Company amortized $ 4,241,429 nil During the year ended August 31, 2023, the Company made cash payments in the aggregate amount of $ 3,001,442 2,833,888 167,554 nil Terragenx On November 17, 2021, Terragenx, a 91 1,875,000 937,500 1 May 17, 2022 33.50 In connection with the $1.875m convertible notes, the Company issued the note holders warrants to purchase a total of 22,388 33.50 The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. 351,240 ● Expected life of 3.0 ● Volatility of 300 ● Dividend yield of 0 ● Risk free interest rate of 0.85 The face amount of the $1.875m convertible notes of $ 1,875,000 1,579,176 295,824 295,824 375,000 90,000 760,824 On June 1, 2022, the Company paid the balance owed on one of two Terragenx $ 1.875 948,874 1.875 192,188 November 29, 2022 937,500 On June 1, 2022, the Company and one of the two Terragenx $ 1.875 November 29, 2022 186,719 Effective February 16, 2023, aside from the Liquidated Damages Charge, the Jefferson Note was paid in full. On August 21, 2023, Jefferson converted the additional Liquidated Damages Charge and the interest thereon. On August 21, 2023, as a result of the conversion, the Company issued 236,511 Novo Integrated – Mast Hill Fund, L.P. On February 23, 2023, the Company entered into a securities purchase agreement (the “Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12 February 23, 2024 573,000 100,000 12 57,300 515,700 1.75 Pursuant to the terms of the Mast Hill Note, the Company agreed to pay accrued interest monthly as well as the Mast Hill Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Mast Hill Note) occurs at an amount equal to the Mast Hill Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any Event of Default, the Mast Hill Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the Mast Hill Principal Sum then outstanding plus accrued interest multiplied by 125 16 The Mast Hill Warrant is exercisable for five years from February 23, 2023, at an exercise price of $ 2.50 86,327 ● Expected life of 5.0 ● Volatility of 252 ● Dividend yield of 0 ● Risk free interest rate of 4.09 As additional consideration for the purchase of the Mast Hill Note and pursuant to the terms of the Mast Hill SPA, on February 24, 2023, the Company issued 95,500 19.99 2,772,045 The principal amount of the $ 573,000 403,710 82,963 86,327 57,300 70,465 297,055 During the year ended August 31, 2023, the principal amount of $ 573,000 6,028 1,750 522,777 nil On September 18, 2023, Mast Hill fully exercised all warrants granted under the terms and conditions of the $ 573,000 53,567 Novo Integrated – FirstFire Global Opportunities Fund, LLC On March 21, 2023, the Company entered into a securities purchase agreement (the “SPA”) with FirstFire Global Opportunities Fund, LLC (“FirstFire”) pursuant to which the Company issued an 12 March 21, 2024 573,000 100,000 12 57,300 515,700 1.75 Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay accrued interest monthly as well as the Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the 2023 FirstFire Note at any time prior to the date that an event of default (as provided in the 2023 FirstFire Note) occurs at an amount equal to the Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any event of default, the 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the Principal Sum then outstanding plus accrued interest multiplied by 125 16 The 2023 FirstFire Warrant is exercisable for five years from March 21, 2023, at an exercise price of $ 2.50 93,811 ● Expected life of 5.0 ● Volatility of 251 ● Dividend yield of 0 ● Risk free interest rate of 3.73 As additional consideration for the purchase of the 2023 FirstFire Note and pursuant to the terms of the SPA, on March 22, 2023, the Company issued 95,500 1,000,000 The principal amount of the $ 573,000 389,057 90,132 93,811 57,300 35,628 The effective conversion price was determined to be $ 1.188 1.390 66,068 The combined total discount is $ 342,938 190,209 nil During the three months ended November 30, 2023, the principal amount of $ 573,000 4,521 519,845 nil On October 12, 2023, FirstFire fully exercised all warrants granted under the terms and conditions of the $ 573,000 53,532 Novo Integrated – Mast Hill Fund, L.P. $445,000 Note, SPA, and Warrant On June 20, 2023, the Company entered into a securities purchase agreement (the “MH $445,000 SPA”) with Mast Hill, pursuant to which the Company issued an 12 June 20, 2024 445,000 77,662 12 44,500 400,500 1.75 Pursuant to the terms of the MH $445,000 Note, the Company agreed to pay accrued interest monthly as well as the MH $ 445,000 44,500 44,500 44,500 77,661 77,661 77,661 85 The Company may prepay the MH $445,000 Note at any time prior to the date that an Event of Default (as defined in the Note) (each an “MH $445,000 Event of Default”) occurs at an amount equal to the MH $445,000 Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any MH $445,000 Event of Default, the MH $445,000 Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the MH $445,000 Principal Sum then outstanding plus accrued interest multiplied by 125 The MH $445,000 Warrant is exercisable for five years from June 20, 2023, at an exercise price of $ 2.50 445,000 77,856 ● Expected life of 5.0 ● Volatility of 251 ● Dividend yield of 0 ● Risk free interest rate of 3.96 As additional consideration for the purchase of the MH $445,000 Note and pursuant to the terms of the MH $445,000 SPA, the Company issued 74,167 1,772,045 The principal amount of the $ 445,000 292,351 74,793 77,856 44,500 39,904 The effective conversion price was determined to be $ 1.150 1.535 97,978 The combined total discount is $ 335,031 83,300 185,823 Specific to the MH $445,000 Note, on July 20, 2023, the Company made a monthly interest payment of $ 4,243 4,535 4,535 4,389 On October 23, 2023, Mast Hill fully exercised all warrants granted under the terms and conditions of the $ 445,000 138,703 September 2023 Mast Hill SPA On September 12, 2023, the Company entered into a securities purchase agreement (the “September 2023 Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12 September 12, 2024 3,500,000 12 350,000 3,150,000 4.50 91.5 Pursuant to the terms of the September 2023 Mast Hill Note, the Company agreed to pay the principal sum and accrued interest as follows: (i) all accrued interest on December 12, 2023, (ii) $ 350,000 350,000 350,000 595,000 595,000 595,000 85 The Company may prepay the September 2023 Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Note) occurs at an amount equal to the principal sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any Event of Default, the September 2023 Mast Hill Note shall become immediately due and payable and the Company will pay to Mast Hill an amount equal to the principal sum then outstanding plus accrued interest multiplied by 125 16 The September 2023 Mast Hill SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the common stock underlying the September 2023 Mast Hill Note. Further, pursuant to the September 2023 Mast Hill SPA, the Company agreed to transfer its rights to the charges/mortgages evidenced by Instrument Nos. CE925256 (in the amount of CDN$ 1,600,000 1,800,000 1,772,045 The Company’s subsidiary, Acenzia Inc. (“Acenzia”), entered into a guaranty with Mast Hill on September 12, 2023. Acenzia guaranteed the repayment of the September 2023 Mast Hill Note and granted Mast Hill a security interest in Acenzia’s assets, including but not limited to, the property located at 1580 Rossi Drive, Tecumseh, Ontario, Canada. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. On September 12, 2023, the Company recorded a derivative liability of $ 3,071,653 ● Expected life of 1 ● Volatility of 182.17 ● Dividend yield of 0 ● Risk free interest rate of 5.42 The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible note. As at November 30, 2023, the fair value of the derivative liability was $ 2,487,726 583,927 ● Expected life of 0.79 ● Volatility of 193.48 ● Dividend yield of 0 ● Risk free interest rate of 5.16 The September 2023 Mast Hill Note contained a discount on note of $ 3,500,000 During the three months ended November 30, 2023, the Company amortized $ 755,464 2,744,536 September 2023 FirstFire SPA & Note On September 18, 2023, the Company entered into a securities purchase agreement (the “September 2023 FirstFire SPA”) with FirstFire Global Opportunities Fund, L.P. (“FirstFire”), pursuant to which the Company issued an 12 September 18, 2024 277,778 12 27,778 250,000 4.50 91.5 Pursuant to the terms of the September 2023 FirstFire Note, the Company agreed to pay the principal sum and accrued interest as follows: (i) all accrued interest on December 18, 2023, (ii) $ 27,778 27,778 27,778 47,222 47,222 47,222 85 The Company may prepay the September 2023 FirstFire Note at any time prior to the date that an event of default occurs at an amount equal to the principal sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any event of default, the September 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the principal sum then outstanding plus accrued interest multiplied by 125 16 The September 2023 FirstFire SPA contains customary representations, warranties, and covenants of the Company, including, among other things and subject to certain exceptions, piggy-back registration rights with respect to the common stock underlying the September 2023 FirstFire Note. In addition to the beneficial ownership limitations provided in the September 2023 FirstFire Note, the sum of the number of shares of common stock that may be issued under the September 2023 FirstFire SPA and September 2023 FirstFire Note shall be limited to 480,156 Acenzia entered into a guaranty with FirstFire on September 18, 2023. Acenzia guaranteed the repayment of the September 2023 FirstFire Note and granted FirstFire a security interest in Acenzia’s assets, including but not limited to the property located at 1580 Rossi Drive, Tecumseh, Ontario, Canada, which is junior in priority to the security interest granted by Acenzia to FirstFire. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. On September 18, 2023, the Company recorded a derivative liability of $ 200,136 ● Expected life of 1 ● Volatility of 180.36 ● Dividend yield of 0 ● Risk free interest rate of 5.44 The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible note. As at November 30, 2023, the fair value of the derivative liability was $ 198,534 1,602 ● Expected life of 0.80 ● Volatility of 193.48 ● Dividend yield of 0 ● Risk free interest rate of 5.16 The September 2023 FirstFire Note contained a discount on note of $ 235,414 During the three months ended November 30, 2023, the Company amortized $ 46,954 188,460

Debentures, Related Parties

Debentures, Related Parties	3 Months Ended
Debentures, Related Parties	Nov. 30, 2023
Debt Disclosure [Abstract]
Debentures, Related Parties	Note 12 – Debentures, Related Parties On September 30, 2013, the Company issued five debentures totaling CAD$ 6,402,512 6,225,163 8 September 30, 2016 September 30, 2019 December 1, 2023 On January 31, 2018, the debenture holders converted 75 3,894,809 414,965 1,047,588 4.11 the average price of the five trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price. On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $ 267,768 At November 30, 2023 and August 31, 2023, the amount of debentures outstanding was $ 913,474 916,824

Leases

Leases	3 Months Ended
Leases	Nov. 30, 2023
Leases
Leases	Note 13 – Leases Operating leases The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2031. The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of November 30, 2023 and August 31, 2023: Schedule of Lease Related Assets and Liabilities November 30, August 31, 2023 2023 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 1,870,204 $ 1,983,898 Total lease assets $ 1,870,204 $ 1,983,898 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 413,506 $ 415,392 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,585,667 1,693,577 Total lease liability $ 1,999,173 $ 2,108,969 Future minimum operating lease payments are as follows: Schedule of Operating Lease Payments Twelve Months Ending November 30, 2024 $ 568,536 2025 494,272 2026 512,495 2027 417,394 2028 223,188 Thereafter 254,641 Total payments 2,470,526 Amount representing interest (471,353 ) Lease obligation, net 1,999,173 Less lease obligation, current portion 413,506 Lease obligation, long-term portion $ 1,585,667 During the three months ended November 30, 2023, the Company did not enter into any new lease obligation. The lease expense for the three months ended November 30, 2023 and 2022 was $ 149,877 209,846 145,545 202,465 3.88 8 Finance Leases The Company leases certain equipment under lease contracts that are accounted for as finance leases. If the contracts meet the criteria for a finance lease, the related equipment underlying the lease contract is capitalized and amortized over its estimated useful life. If the cost of the equipment is not available, the Company calculates the cost by taking the present value of the lease payments using an implicit borrowing rate of 5 The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at November 30, 2023 and August 31, 2023 is as follows: Schedule of Finance Leases November 30, August 31, 2023 2023 Cost $ 209,457 $ 209,457 Accumulated amortization (209,457) (209,457) Net book value $ - $ - Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Twelve Months Ending November 30, 2024 $ 8,973 Total payments 8,973 Amount representing interest (66 ) Lease obligation, net 8,907 Less lease obligation, current portion (8,907 ) Lease obligation, long-term portion $ -

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
Stockholders’ Equity	Nov. 30, 2023
Equity [Abstract]
Stockholders’ Equity	Note 14 – Stockholders’ Equity Reverse Stock Split On November 6, 2023, the Company effectuated a 1-for-10 reverse stock split Convertible Preferred Stock The Company has authorized 1,000,000 0.001 0 0 Common Stock The Company has authorized 499,000,000 0.001 17,291,192 15,759,325 During the three-month period ended November, 2023, the Company issued common stock as follows: ● 80,200 3 80,200 ● 160,200 5 160,200 ● 75,000 September 5, 2023 ● 53,567 573,000 September 18, 2023 ● 75,000 September 18, 2023 ● 519,845 573,000 4,521 577,521 September 21, 2023 ● 75,000 October 3, 2023 ● 73,767 October 9, 2023 ● 53,532 573,000 October 12, 2023 ● 75,000 October 18, 2023 ● 138,703 445,000 October 23, 2023 ● 75,000 November 8, 2023 ● 30,675 November 21, 2023 ● 18,405 November 21, 2023 ● 27,973 1-for-10 reverse stock split Common Stock to be Issued As of November 30, 2023, in connection with the acquisition of 1285 Canada and Poling Taddeo Hovius Physiotherapy Professional Corp, the Company has allotted and is obligated to issue 17,375 44,443 Stock Options On September 8, 2015, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 50,000 On January 16, 2018, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2018 Incentive Compensation Plan (the “2018 Plan”). Under the 2018 Plan, 100,000 86,490 On February 9, 2021, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Under the 2021 Plan, a total of 450,000 the maximum aggregate number of shares that may be issued under the 2021 Plan may be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2024, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan, effective January 1, 2022 and January 1, 2023. As of November 30, 2023, the 2021 Plan had 75,463 On July 26, 2023 and September 29, 2023, the Company’s Board of Directors and stockholders, respectively, approved the Novo Integrated Sciences, Inc. 2023 Equity Incentive Plan (the “2023 Plan”). Under the 2023 Plan, a total of 2,500,000 2,500,000 The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2023 371,423 11.44 3.98 $ 16,000 Granted - Forfeited - Exercised - Outstanding, November 30, 2023 371,423 11.44 3.73 $ - Exercisable, November 30, 2023 371,423 $ 11.44 3.73 $ - The exercise price for stock options outstanding at November 30, 2023: Schedule of Options Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 22,715 $ 13.30 22,715 $ 13.30 54,200 16.00 54,200 16.00 4,800 18.70 4,800 18.70 77,500 30.00 77,500 30.00 7,260 38.00 7,260 38.00 1,000 50.00 1,000 50.00 3,948 19.00 3,948 19.00 200,000 1.32 200,000 1.32 371,423 371,423 No options were granted during the three months ended November 30, 2023 and 2022. The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $ nil 60,887 nil Warrants The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2023 806,254 $ 12.05 3.71 $ 106,960 Granted - Forfeited - Exercised (518,061 ) Outstanding, November 30, 2023 288,193 $ 30.46 3.46 $ 5,400 Exercisable, November 30, 2023 288,193 $ 30.46 3.46 $ 5,400 The exercise price for warrants outstanding at November 30, 2023: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 261,193 $ 33.50 27,000 1.00 288,193

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Nov. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Litigation The Company is party to certain legal proceedings from time-to-time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our condensed consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s unaudited condensed consolidated financial position as of November 30, 2023, results of operations, cash flows or liquidity of the Company. During the period ended November 30, 2023, the Company incurred $ 652,174

Segment Reporting

Segment Reporting	3 Months Ended
Segment Reporting	Nov. 30, 2023
Segment Reporting [Abstract]
Segment Reporting	Note 16 – Segment Reporting ASC Topic 280, Segment Reporting The following tables summarize the Company’s segment information for the three months ended November 30, 2023 and 2022: Schedule of Segment Reporting Information Three Months Ended November 30, 2023 2022 Sales Healthcare services $ 2,044,510 $ 2,021,213 Product manufacturing and development 1,768,458 790,478 Corporate 78,250 607,589 Sales $ 3,891,218 $ 3,419,280 Gross profit Healthcare services $ 676,416 $ 784,031 Product manufacturing and development 1,189,352 347,914 Corporate 78,250 607,588 Gross profit $ 1,944,018 $ 1,739,533 (Loss) income from operations Healthcare services $ (80,327 ) $ (151,691 ) Product manufacturing and development 108,702 (554,842 ) Corporate (3,346,012 ) (1,535,427 ) Income (loss) from operations $ (3,317,637 ) $ (2,241,960 ) Depreciation and amortization Healthcare services $ 30,035 $ 28,968 Product manufacturing and development 262,927 309,042 Corporate 279,442 248,156 Depreciation and amortization $ 572,404 $ 586,166 Capital expenditures Healthcare services $ - $ - Product manufacturing and development - - Corporate - - Capital expenditures $ - $ - Interest expenses Healthcare services $ 20,532 $ 36,303 Product manufacturing and development 462 2,464 Corporate 122,380 128,476 Interest expenses $ 143,374 $ 167,243 Net (loss) income Healthcare services $ (98,640 ) $ (185,713 ) Product manufacturing and development 48,883 (578,576 ) Corporate (4,610,966 ) (3,172,447 ) Net loss $ (4,660,723 ) $ (3,936,736 ) As of November 30, 2023 As of August 31, 2023 Total assets Healthcare services $ 5,002,855 $ 5,158,851 Product Sales 18,748,475 17,993,652 Corporate 13,493,054 12,410,544 $ 37,244,384 $ 35,563,047 Accounts receivable Healthcare services $ 672,841 $ 697,440 Product Sales 1,868,387 765,388 Corporate 94,946 4,200 $ 2,636,174 $ 1,467,028 Intangible assets Healthcare services $ 111,172 $ 120,163 Product Sales 3,592,425 3,818,313 Corporate 12,000,621 12,280,063 $ 15,704,218 $ 16,218,539 Goodwill Healthcare services $ 518,918 $ 520,821 Product Sales 7,035,861 7,061,662 Corporate - - $ 7,554,779 $ 7,582,483

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Nov. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events Purchase and Sale Agreement – Ophir Collection On November 21, 2023, the Company entered into a Purchase and Sale Agreement (“Ophir Agreement”) between the Company and Blake Alsbrook, solely in his capacity as Court-appointed successor receiver (the “Successor Receiver”) in Ocean Thermal Energy Corporation v. C. Robert Coe II, et al., United States District Court for the Central District of California (the “Court”) Case No. 2:19-cv-04299 VAP (JPRx) (the “Action”). Pursuant to the terms of the Ophir Agreement, the Company agreed to purchase, and the Successor Receiver agreed to sell to the Company, the Ophir Collection (as hereinafter defined), subject to the contingencies outlined in the Ophir Agreement, including Court approval, which approval was received on December 1, 2023. The Ophir Agreement was effective upon execution by both parties; however, the Ophir Agreement was subject to approval by the Court. Pursuant to the Court’s July 2, 2019 order in the Action, as modified by the Court’s February 25, 2022 order in the Action, the Successor Receiver has possession of and right to sell a certain collection of 43 gemstones, 42 of which are certified by the Gemological Institute of America, known as the “Ophir Collection”. Together, the Court’s July 2, 2019 order appointing the original receiver, the Court’s December 3, 2019, order appointing the Successor Receiver, and the Court’s February 25, 2022, order are referred to collectively as the “Receivership Orders.” The Receivership Orders authorized the Successor Receiver to take sole custody, possession, and control of the Ophir Collection and to sell, assign, transfer, convey and deliver title and rights in and to the Ophir Collection subject to the approval of the Court to protect the interests of certain identified creditors. Within two business days following the Company’s execution of the Ophir Agreement, the Company was required to, and did, deposit $ 25,000 Pursuant to the terms of the Ophir Agreement, the Company agreed to pay $ 60,000,000 (i) The Company has the right, at all times after November 21, 2023, to conduct a full and unfettered inspection of the Ophir Collection. While the Company has the right to inspect the Ophir Collection prior to closing, the Company’s inspection will not be a contingency to closing and the inability of the Company to inspect (or the Company’s decision not to inspect) the Ophir Collection prior to closing will not delay or prevent closing. (ii) After the Successor Receiver obtains Court approval of the Ophir Agreement, the Company will cause $ 59,975,000 60,000,000 (iii) Within one business day thereafter, the Successor Receiver will assign, transfer, convey and deliver free and clear title and interest in and to, and possession of, the Ophir Collection to the Company. Mast Hill Conversion of Debt on $445,000 Promissory Note On December 21, 2023, the $ 454,071 445,000 457,128 0.99331 445,000 Interest Payment on September 2023 Mast Hill Note On December 12, 2023, the Company made an interest-only payment of $ 104,712 Interest Payment on September 2023 FirstFire Note On December 18, 2023, the Company made an interest-only payment of $ 8,333 Officer Option Grant On January 16, 2024, the Board of Directors granted to Christopher David, the Company’s President, Chief Operating Officer and member of the Board of Directors, an option to purchase 200,000 0.78

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Nov. 30, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to the going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, valuation of derivative liability, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls, including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation.
Noncontrolling Interest	Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss.
Cash Equivalents	Cash Equivalents For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of November 30, 2023 and August 31, 2023, the allowance for uncollectible accounts receivable was $ 855,116 864,215
Inventory	Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of November 30, 2023 and August 31, 2023, the Company’s allowance for slow moving or obsolete inventory was $ nil nil
Other Receivables	Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the three months ended November 30, 2023 and year ended August 31, 2023, the Company wrote off $ nil nil
Property and Equipment	Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5
Leases	Leases The Company applies the provisions of ASC Topic 842, Leases
Long-Lived Assets	Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment no
Intangible Assets	Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its review at November 30, 2023, the Company believes there was no
Right-of-use Assets	Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months
Goodwill	Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. Based on its review at November 30, 2023, the Company believes there was no Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Beginning balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Foreign currency translation adjustment (675 ) (443 ) (783 ) (25,801 ) (2 ) (27,704 ) Balance, November 30, 2023 $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 Ending balance $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779
Fair Value of Financial Instruments	Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, accrued expenses, current portion of finance and operating lease liability, current portion of government loans and notes payable, debentures, convertible notes payable, and due to related parties, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of November 30, 2023 and August 31, 2023, respectively, the Company did not identify any financial assets and liabilities required to be presented on the condensed consolidated balance sheet at fair value, except for contingent liability which is carried at fair value using Level 1 inputs and derivative liability which is carried at fair value using Level 3 inputs.
Derivative Financial Instruments	Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives.
Revenue Recognition	Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery. In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying condensed consolidated balance sheets. Sales returns and allowances were insignificant for the three months ended November 30, 2023 and 2022. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.
Stock-Based Compensation	Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation
Basic and Diluted Earnings Per Share	Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 659,616 1,860,950 3,786,454 17,375 Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented.
Foreign Currency Transactions and Comprehensive Income	Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gain of $ 108,976 922,609
Condensed Consolidated Statements of Cash Flows	Condensed Consolidated Statements of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the condensed consolidated balance sheets.
Segment Reporting	Segment Reporting ASC Topic 280, Segment Reporting two
Reclassifications	Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying condensed consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	3 Months Ended
Organization and Basis of Presentation (Tables)	Nov. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Foreign Currency Translation, Exchange Rate Used	Schedule of Foreign Currency Translation, Exchange Rate Used November 30, 2023 November 30, 2022 August 31, 2023 Period end: CAD to USD exchange rate $ 0.7363 $ 0.7403 $ 0.7390 Average period: CAD to USD exchange rate $ 0.7324 $ 0.7414 $ 0.7426

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Nov. 30, 2023
Accounting Policies [Abstract]
Schedule of Estimated Useful lives of Assets	Schedule of Estimated Useful lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5
Schedule of Intangible Assets Amortized Estimated Useful Lives	The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7
Schedule of Changes in Goodwill	Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,928 ) (3,892 ) (6,878 ) (226,645 ) (18 ) (243,361 ) Balance, August 31, 2023 $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Beginning balance $ 184,750 $ 121,196 $ 214,310 $ 7,061,662 $ 565 $ 7,582,483 Foreign currency translation adjustment (675 ) (443 ) (783 ) (25,801 ) (2 ) (27,704 ) Balance, November 30, 2023 $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779 Ending balance $ 184,075 $ 120,753 $ 213,527 $ 7,035,861 $ 563 $ 7,554,779

Accounts Receivables, Net (Tabl

Accounts Receivables, Net (Tables)	3 Months Ended
Accounts Receivables, Net (Tables)	Nov. 30, 2023
Receivables [Abstract]
Schedule of Accounts Receivable, Net	Accounts receivables, net at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Accounts Receivable, Net November 30, August 31, 2023 2023 Trade receivables $ 3,412,783 $ 2,223,243 Amounts earned but not billed 78,507 108,000 Accounts receivables gross 3,491,290 2,331,243 Allowance for doubtful accounts (855,116 ) (864,215 ) Accounts receivable, net $ 2,636,174 $ 1,467,028

Inventory (Tables)

Inventory (Tables)	3 Months Ended
Inventory (Tables)	Nov. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Inventory November 30, August 31, 2023 2023 Raw materials $ 516,811 $ 388,391 Work in process 108,244 81,696 Finished Goods 645,780 636,896 Inventory Gross 1,270,835 1,106,983 Allowance for slow moving and obsolete inventory - - Inventory, net $ 1,270,835 $ 1,106,983

Other Receivables (Tables)

Other Receivables (Tables)	3 Months Ended
Other Receivables (Tables)	Nov. 30, 2023
Receivables [Abstract]
Schedule of Other Receivables	Other receivables at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Other Receivables November 30, August 31, Advance to corporation; accrues interest at 12 January 31, 2024 $ 73,630 $ 73,900 Advance to corporation; accrues interest at 12 February 1, 2024 532,433 534,386 Advance to corporation; accrues interest at 10 February 1, 2024 441,679 443,298 Total other receivables 1,047,742 1,051,584 Current portion (1,047,742 ) (1,051,584 ) Long-term portion $ - $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
Property and Equipment (Tables)	Nov. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Property and Equipment November 30, August 31, 2023 2023 Land $ 441,780 $ 443,400 Building 3,313,350 3,325,500 Leasehold improvements 838,297 841,371 Clinical equipment 1,909,678 1,916,681 Computer equipment 33,381 33,504 Office equipment 44,400 44,502 Furniture and fixtures 38,149 38,289 Property and Equipment gross 6,619,035 6,643,247 Accumulated depreciation (1,312,422 ) (1,253,209 ) Total $ 5,306,613 $ 5,390,038

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
Intangible Assets (Tables)	Nov. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Intangible Assets November 30, August 31, 2023 2023 Land use rights $ 11,573,321 $ 11,573,321 Intellectual property 7,487,410 7,497,746 Customer relationships 2,287,746 2,291,058 Brand names 1,921,375 1,928,421 Finite lived intangible assets, gross 23,269,852 23,290,546 Accumulated amortization (7,565,634 ) (7,072,007 ) Total $ 15,704,218 $ 16,218,539
Schedule of Expected Amortization Expense of intangible Assets	Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of intangible Assets Twelve Months Ending November 30, 2024 $ 2,003,586 2025 1,820,324 2026 1,454,624 2027 1,208,004 2028 639,025 Thereafter 8,578,655 Total $ 15,704,218

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
Accrued Expenses (Tables)	Nov. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Accrued Expenses November 30, August 31, 2023 2023 Accrued liabilities $ 1,049,543 $ 961,897 Accrued payroll 215,936 236,218 Unearned revenue 35,070 35,434 Accrued expense $ 1,300,549 $ 1,233,549

Government Loans and Notes Pa_2

Government Loans and Notes Payable (Tables)	3 Months Ended
Government Loans and Notes Payable (Tables)	Nov. 30, 2023
Government Loans And Notes Payable
Schedule of Governmental Loans and Note Payable	Notes payable at November 30, 2023 and August 31, 2023 consisted of the following: Schedule of Governmental Loans and Note Payable November 30, August 31, 2023 2023 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program ( A 88,356 88,680 Note payable to the Small Business Administration. The note bears interest at 3.75 190 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 4,000 December 2, 2028 28,589 28,693 Note payable received May 25, 2023, accruing interest at 18 - 73,900 Note payable received May 10, 2023, accruing interest at 15 - 110,850 Total government loans and notes payable 157,265 342,443 Less current portion (93,488 ) (277,405 ) Long-term portion $ 63,777 $ 65,038 (A) The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 58,904 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,452
Schedule of Future Maturities Outstanding of government Loans and Notes Payable	Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of government Loans and Notes Payable Twelve Months Ending November 30, 2024 $ 93,488 2025 6,470 2026 6,469 2027 6,469 2028 6,469 Thereafter 37,900 Total $ 157,265

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Nov. 30, 2023
Leases
Schedule of Lease Related Assets and Liabilities	The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of November 30, 2023 and August 31, 2023: Schedule of Lease Related Assets and Liabilities November 30, August 31, 2023 2023 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 1,870,204 $ 1,983,898 Total lease assets $ 1,870,204 $ 1,983,898 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 413,506 $ 415,392 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,585,667 1,693,577 Total lease liability $ 1,999,173 $ 2,108,969
Schedule of Operating Lease Payments	Future minimum operating lease payments are as follows: Schedule of Operating Lease Payments Twelve Months Ending November 30, 2024 $ 568,536 2025 494,272 2026 512,495 2027 417,394 2028 223,188 Thereafter 254,641 Total payments 2,470,526 Amount representing interest (471,353 ) Lease obligation, net 1,999,173 Less lease obligation, current portion 413,506 Lease obligation, long-term portion $ 1,585,667
Schedule of Finance Leases	The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at November 30, 2023 and August 31, 2023 is as follows: Schedule of Finance Leases November 30, August 31, 2023 2023 Cost $ 209,457 $ 209,457 Accumulated amortization (209,457) (209,457) Net book value $ - $ -
Schedule of Future Minimum Lease Payments	Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Twelve Months Ending November 30, 2024 $ 8,973 Total payments 8,973 Amount representing interest (66 ) Lease obligation, net 8,907 Less lease obligation, current portion (8,907 ) Lease obligation, long-term portion $ -

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
Stockholders’ Equity (Tables)	Nov. 30, 2023
Equity [Abstract]
Schedule of Stock Option Activity	The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2023 371,423 11.44 3.98 $ 16,000 Granted - Forfeited - Exercised - Outstanding, November 30, 2023 371,423 11.44 3.73 $ - Exercisable, November 30, 2023 371,423 $ 11.44 3.73 $ -
Schedule of Options Outstanding and Exercisable	The exercise price for stock options outstanding at November 30, 2023: Schedule of Options Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 22,715 $ 13.30 22,715 $ 13.30 54,200 16.00 54,200 16.00 4,800 18.70 4,800 18.70 77,500 30.00 77,500 30.00 7,260 38.00 7,260 38.00 1,000 50.00 1,000 50.00 3,948 19.00 3,948 19.00 200,000 1.32 200,000 1.32 371,423 371,423
Schedule of Warrant Activity	The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2023 806,254 $ 12.05 3.71 $ 106,960 Granted - Forfeited - Exercised (518,061 ) Outstanding, November 30, 2023 288,193 $ 30.46 3.46 $ 5,400 Exercisable, November 30, 2023 288,193 $ 30.46 3.46 $ 5,400
Schedule of Warrants Outstanding	The exercise price for warrants outstanding at November 30, 2023: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 261,193 $ 33.50 27,000 1.00 288,193

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
Segment Reporting (Tables)	Nov. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following tables summarize the Company’s segment information for the three months ended November 30, 2023 and 2022: Schedule of Segment Reporting Information Three Months Ended November 30, 2023 2022 Sales Healthcare services $ 2,044,510 $ 2,021,213 Product manufacturing and development 1,768,458 790,478 Corporate 78,250 607,589 Sales $ 3,891,218 $ 3,419,280 Gross profit Healthcare services $ 676,416 $ 784,031 Product manufacturing and development 1,189,352 347,914 Corporate 78,250 607,588 Gross profit $ 1,944,018 $ 1,739,533 (Loss) income from operations Healthcare services $ (80,327 ) $ (151,691 ) Product manufacturing and development 108,702 (554,842 ) Corporate (3,346,012 ) (1,535,427 ) Income (loss) from operations $ (3,317,637 ) $ (2,241,960 ) Depreciation and amortization Healthcare services $ 30,035 $ 28,968 Product manufacturing and development 262,927 309,042 Corporate 279,442 248,156 Depreciation and amortization $ 572,404 $ 586,166 Capital expenditures Healthcare services $ - $ - Product manufacturing and development - - Corporate - - Capital expenditures $ - $ - Interest expenses Healthcare services $ 20,532 $ 36,303 Product manufacturing and development 462 2,464 Corporate 122,380 128,476 Interest expenses $ 143,374 $ 167,243 Net (loss) income Healthcare services $ (98,640 ) $ (185,713 ) Product manufacturing and development 48,883 (578,576 ) Corporate (4,610,966 ) (3,172,447 ) Net loss $ (4,660,723 ) $ (3,936,736 ) As of November 30, 2023 As of August 31, 2023 Total assets Healthcare services $ 5,002,855 $ 5,158,851 Product Sales 18,748,475 17,993,652 Corporate 13,493,054 12,410,544 $ 37,244,384 $ 35,563,047 Accounts receivable Healthcare services $ 672,841 $ 697,440 Product Sales 1,868,387 765,388 Corporate 94,946 4,200 $ 2,636,174 $ 1,467,028 Intangible assets Healthcare services $ 111,172 $ 120,163 Product Sales 3,592,425 3,818,313 Corporate 12,000,621 12,280,063 $ 15,704,218 $ 16,218,539 Goodwill Healthcare services $ 518,918 $ 520,821 Product Sales 7,035,861 7,061,662 Corporate - - $ 7,554,779 $ 7,582,483

Schedule of Foreign Currency Tr

Schedule of Foreign Currency Translation, Exchange Rate Used (Details)	Nov. 30, 2023	Aug. 31, 2023	Nov. 30, 2022
Period End [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7363	0.7390	0.7403
Average Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7324	0.7426	0.7414

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details Narrative) - USD ($)					3 Months Ended
	Nov. 07, 2023	Nov. 06, 2023	May 09, 2017	Apr. 25, 2017	Nov. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split	1-for-10 reverse stock split	1-for-10 reverse stock split			1-for-10 reverse stock split
Parent Company [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock issued in connection with reverse merger transaction			$ 6,904
Share Exchange Agreement [Member] \| NHL [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of restricted shares of common stock, shares				1,677,974
Percentage of common stock issued and outstanding				85%

Schedule of Estimated Useful li

Schedule of Estimated Useful lives of Assets (Details)	Nov. 30, 2023
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	30 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years

Schedule of Intangible Assets A

Schedule of Intangible Assets Amortized Estimated Useful Lives (Details)	Nov. 30, 2023
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	50 years
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	5 years
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years

Schedule of Changes in Goodwill

Schedule of Changes in Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
Schedule of Changes in Goodwill (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Beginning balance	$ 7,582,483	$ 7,825,844
Foreign currency translation adjustment	(27,704)	(243,361)
Ending balance	7,554,779	7,582,483
APKA Health, Inc. [Member]
Beginning balance	184,750	190,678
Foreign currency translation adjustment	(675)	(5,928)
Ending balance	184,075	184,750
Executive Fitness Leaders [Member]
Beginning balance	121,196	125,088
Foreign currency translation adjustment	(443)	(3,892)
Ending balance	120,753	121,196
Rockland [Member]
Beginning balance	214,310	221,188
Foreign currency translation adjustment	(783)	(6,878)
Ending balance	213,527	214,310
Acenzia Inc [Member]
Beginning balance	7,061,662	7,288,307
Foreign currency translation adjustment	(25,801)	(226,645)
Ending balance	7,035,861	7,061,662
12858461 Canada Corp [Member]
Beginning balance	565	583
Foreign currency translation adjustment	(2)	(18)
Ending balance	$ 563	$ 565

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)		3 Months Ended		12 Months Ended
	Nov. 07, 2023 shares	Nov. 30, 2023 USD ($) Integer shares	Nov. 30, 2022 USD ($) shares	Aug. 31, 2023 USD ($)
Allowance for uncollectible accounts receivable		$ 855,116		$ 864,215
Inventory
Other receivable written off
Impairment of long-lived assets		0
Impairment of intangible assets		$ 0
Contract lease term		12 months
Goodwill impairment charge
Debt conversion, converted instrument, shares issued \| shares	27,973
Foreign currency translation gain (loss)		$ 108,976	$ (420,982)	$ 922,609
Number of reportable segments \| Integer		2
Common Stock [Member]
Debt conversion, converted instrument, shares issued \| shares		3,786,454
Common Stock To Be Issued [Member]
Debt conversion, converted instrument, shares issued \| shares		17,375
Options/Warrants Outstanding [Member]
Potentially dilutive common stock options and warrants outstanding, shares \| shares		659,616	1,860,950
Terragenx Inc [Member]
Equity method investment, ownership percentage		91%
12858461 Canada Corp [Member]
Equity method investment, ownership percentage		50.10%
Novo Healthnet Kemptville Centre Inc [Member]
Equity method investment, ownership percentage		80%
Novo Earth Therapeutics Inc [Member]
Equity method investment, ownership percentage		70%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
Related Party Transactions (Details Narrative) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
6% Interest Rate [Member]
Related Party Transaction [Line Items]
Bearing interest rate	6%	6%
13.75% Interest Rate [Member]
Related Party Transaction [Line Items]
Bearing interest rate	13.75%	13.75%
Related Party [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 458,266	$ 533,001
Related Party [Member] \| Non-Interest Bearing [Member]
Related Party Transaction [Line Items]
Due to related parties	376,701	451,137
Related Party [Member] \| 6% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties		21,267
Related Party [Member] \| 13.75% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 81,565	$ 60,597

Schedule of Accounts Receivable

Schedule of Accounts Receivable, Net (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Receivables [Abstract]
Trade receivables	$ 3,412,783	$ 2,223,243
Amounts earned but not billed	78,507	108,000
Accounts receivables gross	3,491,290	2,331,243
Allowance for doubtful accounts	(855,116)	(864,215)
Accounts receivable, net	$ 2,636,174	$ 1,467,028

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 516,811	$ 388,391
Work in process	108,244	81,696
Finished Goods	645,780	636,896
Inventory Gross	1,270,835	1,106,983
Allowance for slow moving and obsolete inventory
Inventory, net	$ 1,270,835	$ 1,106,983

Schedule of Other Receivables (

Schedule of Other Receivables (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 1,047,742	$ 1,051,584
Current portion	(1,047,742)	(1,051,584)
Long-term portion
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	73,630	73,900
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	532,433	534,386
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 441,679	$ 443,298

Schedule of Other Receivables_2

Schedule of Other Receivables (Details) (Parenthetical)	3 Months Ended	12 Months Ended
Schedule of Other Receivables (Details) (Parenthetical)	Nov. 30, 2023	Aug. 31, 2023
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%
Notes receivable due date	Jan. 31, 2024	Jan. 31, 2024
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%
Notes receivable due date	Feb. 01, 2024	Feb. 01, 2024
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	10%	10%
Notes receivable due date	Feb. 01, 2024	Feb. 01, 2024

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Property, Plant and Equipment [Line Items]
Property and Equipment gross	$ 6,619,035	$ 6,643,247
Accumulated depreciation	(1,312,422)	(1,253,209)
Total	5,306,613	5,390,038
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	441,780	443,400
Building [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	3,313,350	3,325,500
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	838,297	841,371
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	1,909,678	1,916,681
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	33,381	33,504
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	44,400	44,502
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	$ 38,149	$ 38,289

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Nov. 30, 2023	Nov. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 72,604	$ 60,043

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 23,269,852	$ 23,290,546
Accumulated amortization	(7,565,634)	(7,072,007)
Total	15,704,218	16,218,539
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	11,573,321	11,573,321
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	7,487,410	7,497,746
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	2,287,746	2,291,058
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 1,921,375	$ 1,928,421

Schedule of Expected Amortizati

Schedule of Expected Amortization Expense of intangible Assets (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 2,003,586
2025	1,820,324
2026	1,454,624
2027	1,208,004
2028	639,025
Thereafter	8,578,655
Total	$ 15,704,218	$ 16,218,539

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Nov. 30, 2023	Nov. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 499,800	$ 526,123

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Payables and Accruals [Abstract]
Accrued liabilities	$ 1,049,543	$ 961,897
Accrued payroll	215,936	236,218
Unearned revenue	35,070	35,434
Accrued expense	$ 1,300,549	$ 1,233,549

Schedule of Governmental Loans

Schedule of Governmental Loans and Note Payable (Details) - USD ($)		3 Months Ended	12 Months Ended
		Nov. 30, 2023	Aug. 31, 2023
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 157,265	$ 342,443
Less current portion		(93,488)	(277,405)
Long-term portion		63,777	65,038
Notes Payable One [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable	[1]	88,356	88,680
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		40,320	40,320
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 28,589	$ 28,693
Debt instrument, maturity date		Dec. 02, 2028	Dec. 02, 2028
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable			$ 73,900
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable			$ 110,850

[1]The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 58,904 January 18, 2024 If the loan amount is paid on or before January 18, 2024, 25 75 5 60,000 20,000 29,452

Schedule of Governmental Loan_2

Schedule of Governmental Loans and Note Payable (Details) (Parenthetical)	3 Months Ended		12 Months Ended
	Nov. 30, 2023 USD ($)	Nov. 30, 2023 CAD ($)	Aug. 31, 2023 USD ($)	Nov. 30, 2023 CAD ($)
Short-Term Debt [Line Items]
Default in repayment rate	75%	75%
Interest rate during fixed rate	5%			5%
Canada Emergency Business Account Loan [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date	Jan. 18, 2024	Jan. 18, 2024
Debt description	If the loan amount is paid on or before January 18, 2024, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before January 18, 2024, the Early Payment Credit will not apply	If the loan amount is paid on or before January 18, 2024, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before January 18, 2024, the Early Payment Credit will not apply
Forgiveness percentage	25%	25%
Canada Emergency Business Account Loan [Member] \| Terragenx [Member]
Short-Term Debt [Line Items]
Notes Payable	$ 29,452			$ 60,000
Repayment of debt		$ 20,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	3.75%	3.75%	3.75%
Periodic payment	$ 190		$ 190
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	4.53%	4.53%	4.53%
Periodic payment	$ 4,000		$ 4,000
Debt instrument, maturity date	Dec. 02, 2028	Dec. 02, 2028	Dec. 02, 2028
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	18%	18%	18%
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate during period	15%	15%	15%
Canada Emergency Business Account Loan [Member]
Short-Term Debt [Line Items]
Notes Payable	$ 58,904			$ 80,000

Schedule of Future Maturities O

Schedule of Future Maturities Outstanding of government Loans and Notes Payable (Details)	Nov. 30, 2023 USD ($)
Government Loans And Notes Payable
2024	$ 93,488
2025	6,470
2026	6,469
2027	6,469
2028	6,469
Thereafter	37,900
Total	$ 157,265

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)																																																		1 Months Ended	3 Months Ended		12 Months Ended
Convertible Notes Payable (Details Narrative)	Aug. 18, 2024 USD ($)	Aug. 12, 2024 USD ($)	Jul. 18, 2024 USD ($)	Jul. 12, 2024 USD ($)	Jun. 18, 2024 USD ($)	Jun. 12, 2024 USD ($)	May 18, 2024 USD ($)	May 12, 2024 USD ($)	Apr. 20, 2024 USD ($)	Apr. 18, 2024 USD ($)	Apr. 12, 2024 USD ($)	Mar. 20, 2024 USD ($)	Mar. 18, 2024 USD ($)	Mar. 12, 2024 USD ($)	Feb. 21, 2024 USD ($)	Feb. 20, 2024 USD ($)	Jan. 23, 2024 USD ($)	Jan. 21, 2024 USD ($)	Jan. 20, 2024 USD ($)	Jan. 16, 2024 shares	Dec. 23, 2023 USD ($)	Dec. 21, 2023 USD ($)	Dec. 21, 2023 USD ($) shares	Dec. 20, 2023 USD ($)	Dec. 18, 2023 USD ($)	Dec. 12, 2023 USD ($)	Nov. 23, 2023 USD ($)	Nov. 21, 2023 USD ($)	Nov. 07, 2023 shares	Oct. 23, 2023 USD ($) shares	Oct. 21, 2023 USD ($)	Oct. 12, 2023 USD ($) shares	Sep. 23, 2023 USD ($)	Sep. 21, 2023 USD ($)	Sep. 18, 2023 USD ($) $ / shares shares	Sep. 12, 2023 USD ($) $ / shares shares	Sep. 12, 2023 CAD ($) shares	Aug. 23, 2023 USD ($)	Aug. 21, 2023 USD ($) shares	Jun. 20, 2023 USD ($) $ / shares shares	Jun. 20, 2023 USD ($) $ / shares shares	May 20, 2023 USD ($)	Mar. 21, 2023 USD ($) $ / shares shares	Feb. 24, 2023 shares	Feb. 23, 2023 USD ($) $ / shares shares	Nov. 14, 2022 USD ($)	Jun. 01, 2022 USD ($)	Dec. 14, 2021 USD ($) $ / shares shares	Nov. 17, 2021 USD ($) $ / shares shares	Sep. 30, 2023 USD ($)	Nov. 30, 2023 USD ($) shares	Nov. 30, 2022 USD ($) shares	Aug. 31, 2023 USD ($) shares	Oct. 20, 2023 USD ($)	Sep. 12, 2023 CAD ($)	Jul. 20, 2023 USD ($)
Debt face amount																																																	$ 1,875,000
Convertible notes payable, note holders issued warrants to purchase total, shares \| shares																																																	22,388
Estimated value warrants																																																	$ 351,240
Discount on convertable note and additional paid in capital																																																	295,824
Loan fees																																																	$ 90,000
Debt amortized discount																																																			$ 1,075,928	$ 1,490,513
Debt converted into common stock \| shares																													27,973
Share price \| $ / shares																																																	$ 33.50
Redemption of warrants description																																																	The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction.
Convertible notes payable																																																	$ 1,579,176
Original issue discount																																																	$ 375,000
Convertible notes payable																																																			1,103,959		$ 558,668
Common stock issuable upon exercise																																																			577,522
Change in fair value of derivative liability																																																			(585,529)
Subsequent Event [Member]
Debt converted into common stock \| shares																							457,128
Mast Hill Securities Purchase Agreement [Member]
Debt face amount																						$ 445,000	$ 445,000													$ 3,500,000				$ 445,000	$ 445,000				$ 573,000
Maturity date																																				Sep. 12, 2024	Sep. 12, 2024			Jun. 20, 2024					Feb. 23, 2024
Debt conversion price \| $ / shares																																				$ 4.50				$ 1.75	$ 1.75				$ 1.75
Exercise price of warrants or rights \| $ / shares																																								$ 2.50	$ 2.50				$ 2.50
Estimated value warrants																																													$ 86,327
Debt instrument, unamortized discount																																													57,300						2,744,536
Loan fees																																								$ 39,904	$ 39,904				70,465
Debt amortized discount																																													$ 297,055					$ 3,500,000	755,464
Fair value of the derivative liability																																				$ 3,071,653															$ 2,487,726
Accrued interest																																																					$ 6,028
Debt converted into common stock \| shares																																																					522,777
Debt instrument aggregate principal amount																																																					$ 573,000
Share price \| $ / shares																																								$ 1.535	$ 1.535
Original issue discount																																				$ 350,000				$ 44,500	$ 44,500
Convertible notes payable																																		$ 4,535					$ 4,535															$ 4,389		$ 4,243
Debt instrument, interest rate, effective percentage																																				12%				12%	12%				12%										12%
Class of warrant or right, number of shares \| shares																																								1,772,045	1,772,045				2,772,045
Accrued liabilities																											$ 100,000			$ 57,300			$ 57,300					$ 57,300				$ 77,661
Percentage of stock price trigger																																				85%	85%			85%					85%
Administrative fees expense																																				$ 750				$ 750					$ 750
Variable interest, percentage rate																																				125%				125%	125%				125%										125%
Number of restricted shares \| shares																																												95,500							53,567
Percentage of issued and outstanding common stock																																													19.99%
Other fees																																																					1,750
Debt instrument, effective conversion price \| $ / shares																																								$ 1.150	$ 1.150
Beneficial conversion feature																																									$ 97,978
Payments for repurchase of warrants																																								$ 400,500
Common stock issuable upon exercise																																									445,000
Estimated value of the warrants																																									$ 77,856
Shares new issues \| shares																																				1,772,045	1,772,045			74,167
Repayments of debt																																				$ 3,150,000
Percentage of stock price trigger																																				0.915	0.915
Restructuring charges																																					$ 1,600,000
Financial instruments owned, mortgages																																																							$ 1,800,000
Change in fair value of derivative liability																																																			$ 583,927
Mast Hill Securities Purchase Agreement [Member] \| Subsequent Event [Member]
Debt interest amount																										$ 104,712
Accrued liabilities																	$ 100,000
Mast Hill Securities Purchase Agreement [Member] \| Forecast [Member]
Accrued liabilities		$ 595,000		$ 595,000		$ 595,000		$ 350,000	$ 77,661		$ 350,000	$ 77,661		$ 350,000		$ 44,500			$ 44,500		$ 100,000			$ 445,000
Mast Hill Securities Purchase Agreement [Member] \| Maximum [Member]
Class of warrant or right, number of shares \| shares																																								77,662	77,662				100,000
Variable interest, percentage rate																																				16%									16%										16%
Mast Hill Note and Mast Hill Warrant [Member]
Debt instrumment converted amount																																													$ 515,700
MastHill Warrant Agreement [Member]
Number of restricted shares \| shares																														138,703					53,567
Proceeds from warrant exercises																														$ 445,000					$ 573,000
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt face amount																																											$ 573,000
Maturity date																																											Mar. 21, 2024
Debt conversion price \| $ / shares																																											$ 1.75
Exercise price of warrants or rights \| $ / shares																																											$ 2.50
Estimated value warrants																																											$ 93,811
Debt instrument, unamortized discount																																											57,300
Loan fees																																											35,628
Debt amortized discount																																											$ 342,938								190,209
Accrued interest																																																			$ 4,521
Debt converted into common stock \| shares																																																			519,845
Debt instrument aggregate principal amount																																																			$ 573,000
Share price \| $ / shares																																											$ 1.390
Debt instrument, interest rate, effective percentage																																											12%
Class of warrant or right, number of shares \| shares																																											1,000,000
Accrued liabilities																												$ 57,300			$ 57,300			$ 57,300
Percentage of stock price trigger																																											85%
Administrative fees expense																																											$ 750
Variable interest, percentage rate																																											125%
Number of restricted shares \| shares																																											95,500
Debt instrument, effective conversion price \| $ / shares																																											$ 1.188
Beneficial conversion feature																																											$ 66,068
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] \| Forecast [Member]
Accrued liabilities															$ 100,000			$ 100,000				$ 100,000
First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member] \| Maximum [Member]
Class of warrant or right, number of shares \| shares																																											100,000
Variable interest, percentage rate																																											16%
First Fire Note and First Fire Warrant [Member]
Debt instrumment converted amount																																											$ 515,700
First Fire Warrant Agreement [Member]
Debt face amount																																																			$ 573,000
Number of restricted shares \| shares																																53,532																			53,532
Proceeds from warrant exercises																																$ 573,000
FirstFire Securities Purchase Agreement [Member]
Debt face amount																																			$ 277,778
Maturity date																																			Sep. 18, 2024
Debt conversion price \| $ / shares																																			$ 4.50
Debt instrument, unamortized discount																																																			$ 188,460
Debt amortized discount																																																		$ 235,414	46,954
Fair value of the derivative liability																																			$ 200,136																198,534
Original issue discount																																			$ 27,778
Debt instrument, interest rate, effective percentage																																			12%
Percentage of stock price trigger																																			85%
Administrative fees expense																																			$ 750
Variable interest, percentage rate																																			125%
Shares new issues \| shares																																				480,156	480,156
Repayments of debt																																			$ 250,000
Percentage of stock price trigger																																			0.915
Change in fair value of derivative liability																																																			$ 1,602
FirstFire Securities Purchase Agreement [Member] \| Subsequent Event [Member]
Debt interest amount																									$ 8,333
FirstFire Securities Purchase Agreement [Member] \| Forecast [Member]
Accrued liabilities	$ 47,222		$ 47,222		$ 47,222		$ 27,778			$ 27,778			$ 27,778
FirstFire Securities Purchase Agreement [Member] \| Maximum [Member]
Variable interest, percentage rate																																			16%
Terragenx Inc [Member]
Ownership percentage																																																	91%
Terragenx Inc [Member] \| Promissory Notes Payment [Member]
Convertible notes payable																																															$ 1,875,000
Notes payable																																															948,874
Terragenx Inc [Member] \| Promissory Notes Payment and Extension [Member]
Convertible notes payable																																															1,875,000
Notes payable																																															937,500
Convertible notes payable																																															$ 192,188
Maturity date																																															Nov. 29, 2022
Jefferson Street Capital [Member]
Debt converted into common stock \| shares																																							236,511
Convertible notes payable																																															$ 1,875,000
Notes payable																																															$ 186,719
Maturity date																																															Nov. 29, 2022
Warrant [Member]
Debt face amount																																																$ 5,257,466
Warrants and rights outstanding, term																																																			3 years
Shares new issues \| shares																																																			80,200
Warrant [Member] \| Mast Hill Securities Purchase Agreement [Member]
Debt face amount																																								$ 77,856	$ 77,856				86,327
Warrant [Member] \| First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt face amount																																											93,811
Common Stock [Member]
Debt converted into common stock \| shares																																																			3,786,454
Common stock issuable upon exercise																																																			$ 520
Shares new issues \| shares																																																				400,000
Common Stock [Member] \| Subsequent Event [Member]
Shares new issues \| shares																				200,000
Common Stock [Member] \| Mast Hill Securities Purchase Agreement [Member]
Debt face amount																																								74,793	74,793				82,963
Common Stock [Member] \| First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt face amount																																											90,132
Convertible Debt [Member]
Debt face amount																																																$ 11,409,200
Convertible Debt [Member] \| Mast Hill Securities Purchase Agreement [Member]
Debt face amount																																								$ 292,351	$ 292,351				$ 403,710
Convertible Debt [Member] \| First Fire Global Opportunities Fund LLC Securities Purchase Agreement [Member]
Debt face amount																																											$ 389,057
Convertible Notes [Member]
Debt amortized discount																																																	$ 760,824
Debt description																																														(i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion.
Measurement Input, Expected Term [Member]
Warrants and rights outstanding, term																																								5 years	5 years		5 years		5 years			4 years	3 years
Derivative liability, measurement input, term																																			1 year	1 year	1 year									6 months 29 days
Measurement Input, Expected Term [Member] \| Mast Hill Securities Purchase Agreement [Member]
Derivative liability, measurement input, term																																																			9 months 14 days
Measurement Input, Expected Term [Member] \| FirstFire Securities Purchase Agreement [Member]
Derivative liability, measurement input, term																																																			9 months 18 days
Measurement Input, Price Volatility [Member]
Warrants measurement input percentage																																								251	251		251		252			275	300
Derivative liability measurement input percentage																																			180.36	182.17										148.20									182.17
Measurement Input, Price Volatility [Member] \| Mast Hill Securities Purchase Agreement [Member]
Derivative liability measurement input percentage																																																			193.48
Measurement Input, Price Volatility [Member] \| FirstFire Securities Purchase Agreement [Member]
Derivative liability measurement input percentage																																																			193.48
Measurement Input, Expected Dividend Rate [Member]
Warrants measurement input percentage																																								0	0		0		0			0	0
Derivative liability measurement input percentage																																			0	0										0									0
Measurement Input, Expected Dividend Rate [Member] \| Mast Hill Securities Purchase Agreement [Member]
Derivative liability measurement input percentage																																																			0
Measurement Input, Expected Dividend Rate [Member] \| FirstFire Securities Purchase Agreement [Member]
Derivative liability measurement input percentage																																																			0
Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input percentage																																								3.96	3.96		3.73		4.09			1.23	0.85
Derivative liability measurement input percentage																																			5.44	5.42										4.55									5.42
Measurement Input, Risk Free Interest Rate [Member] \| Mast Hill Securities Purchase Agreement [Member]
Derivative liability measurement input percentage																																																			5.16
Measurement Input, Risk Free Interest Rate [Member] \| FirstFire Securities Purchase Agreement [Member]
Derivative liability measurement input percentage																																																			5.16
Two Convertible Notes [Member]
Debt face amount																																																$ 16,666,666					8,396,666
Interest Rate, Stated Percentage																																																5%
Maturity date																																																Jun. 14, 2023
Debt conversion price \| $ / shares																																																$ 20
Convertible notes payable, note holders issued warrants to purchase total, shares \| shares																																																583,334
Exercise price of warrants or rights \| $ / shares																																																$ 20
Warrant maturity date																																																Dec. 14, 2025
Estimated value warrants																																																$ 7,680,156
Discount on convertable note and additional paid in capital																																																5,257,466
Debt instrument, unamortized discount																																																1,666,666
Loan fees																																																1,140,000
Debt amortized discount																																																8,064,132					4,241,429
Debt face amount																																																					2,833,888
Derivative Liability, Current, Statement of Financial Position [Extensible Enumeration]																																														Convertible notes payable
Fair value of the derivative liability																																														$ 1,390,380
Accrued interest																																																					$ 32,559
Debt converted into common stock \| shares																																																					8,527,835
Debt instrumment converted amount																																																					$ 1,000,000
Extinguishment of derivative liability due to conversion																																																					1,390,380
Amortization payment																																																					3,001,442
Debt interest amount																																																					167,554
Debt instrument aggregate principal amount
Two Convertible Notes [Member] \| Terragenx Inc [Member]
Debt face amount																																																	$ 1,875,000
Interest Rate, Stated Percentage																																																	1%
Maturity date																																																	May 17, 2022
Convertible Debt Two [Member]
Debt face amount																																																$ 8,333,333
Debt face amount																																														1,000,000
Convertible Debt Two [Member] \| Terragenx Inc [Member]
Debt face amount																																																	$ 937,500
Convertible Debt One [Member]
Debt face amount																																														$ 1,000,000
Convertible Notes [Member] \| Mast Hill Securities Purchase Agreement [Member]
Debt instrument, unamortized discount																																																			185,823
Debt amortized discount																																									$ 335,031										$ 83,300

Debentures, Related Parties (De

Debentures, Related Parties (Details Narrative)							3 Months Ended
Debentures, Related Parties (Details Narrative)	Nov. 07, 2023 shares	Nov. 02, 2021	Jul. 21, 2020 USD ($)	Jan. 31, 2018 USD ($) $ / shares shares	Dec. 02, 2017	Sep. 30, 2013 USD ($)	Nov. 30, 2023 USD ($)	Nov. 30, 2022 USD ($)	Sep. 30, 2013 CAD ($)
Short-Term Debt [Line Items]
Debentures, outstanding							$ 913,474	$ 916,824
Debt converted, shares issued \| shares	27,973
Repayment of related party debt			$ 267,768				$ (72,402)	$ (48,480)
Five Debentures [Member]
Short-Term Debt [Line Items]
Debentures, outstanding						$ 6,225,163			$ 6,402,512
Debt interest rate						8%			8%
Debt due date		Dec. 01, 2023			Sep. 30, 2019	Sep. 30, 2016
Debentures [Member]
Short-Term Debt [Line Items]
Debentures, outstanding				$ 3,894,809
Percentage of debt converted				75%
Accrued interest				$ 414,965
Debt converted, shares issued \| shares				1,047,588
Debt conversion price \| $ / shares				$ 4.11
Debt conversion description				the average price of the five trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

Schedule of Lease Related Asset

Schedule of Lease Related Assets and Liabilities (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Leases
Operating lease assets	$ 1,870,204	$ 1,983,898
Total lease assets	1,870,204	1,983,898
Current liabilities- Operating lease liability	413,506	415,392
Noncurrent liabilities - Operating lease liability	1,585,667	1,693,577
Total lease liability	$ 1,999,173	$ 2,108,969

Schedule of Operating Lease Pay

Schedule of Operating Lease Payments (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Leases
2024	$ 568,536
2025	494,272
2026	512,495
2027	417,394
2028	223,188
Thereafter	254,641
Total payments	2,470,526
Amount representing interest	(471,353)
Total lease liability	1,999,173	$ 2,108,969
Less lease obligation, current portion	413,506	415,392
Lease obligation, long-term portion	$ 1,585,667	$ 1,693,577

Schedule of Finance Leases (Det

Schedule of Finance Leases (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Leases
Cost	$ 209,457	$ 209,457
Accumulated amortization	(209,457)	(209,457)
Net book value
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net	Property and equipment, net

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Leases
2024	$ 8,973
Total payments	8,973
Amount representing interest	(66)
Lease obligation, net	8,907
Less lease obligation, current portion	(8,907)	$ (11,744)
Lease obligation, long-term portion

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended
Leases (Details Narrative) - USD ($)	Nov. 30, 2023	Nov. 30, 2022
Leases
Lease expense	$ 149,877	$ 209,846
Cash paid under operating leases	$ 145,545	$ 202,465
Weighted average remaning lease term	3 years 10 months 17 days
Weighted average discount rate	8%
Lease payments implicit borrowing rate	5%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
Schedule of Stock Option Activity (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Equity [Abstract]
Options outstanding, balance	371,423
Weighted average exercise price, outstanding, balance	$ 11.44
Weighted average remaining contractual life, outstanding	3 years 8 months 23 days	3 years 11 months 23 days
Aggregate intrinsic value, outstanding, balance	$ 16,000
Options outstanding, granted
Options outstanding, forfeited
Options outstanding, exercised
Options outstanding, balance	371,423	371,423
Weighted average exercise price, outstanding, balance	$ 11.44	$ 11.44
Aggregate intrinsic value, outstanding, balance		$ 16,000
Options outstanding, exercisable	371,423
Weighted average exercise price, exercisable	$ 11.44
Weighted average remaining contractual life, Exercisable	3 years 8 months 23 days
Aggregate intrinsic value, Exercisable

Schedule of Options Outstanding

Schedule of Options Outstanding and Exercisable (Details) - $ / shares	Nov. 30, 2023	Aug. 31, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	371,423	371,423
Number of options, exercisable	371,423
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	22,715
Exercise price, outstanding	$ 13.30
Number of options, exercisable	22,715
Exercise price, exercisable	$ 13.30
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	54,200
Exercise price, outstanding	$ 16
Number of options, exercisable	54,200
Exercise price, exercisable	$ 16
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	4,800
Exercise price, outstanding	$ 18.70
Number of options, exercisable	4,800
Exercise price, exercisable	$ 18.70
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	77,500
Exercise price, outstanding	$ 30
Number of options, exercisable	77,500
Exercise price, exercisable	$ 30
Exercise Price Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	7,260
Exercise price, outstanding	$ 38
Number of options, exercisable	7,260
Exercise price, exercisable	$ 38
Exercise Price Range Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	1,000
Exercise price, outstanding	$ 50
Number of options, exercisable	1,000
Exercise price, exercisable	$ 50
Exercise Price Range Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	3,948
Exercise price, outstanding	$ 19
Number of options, exercisable	3,948
Exercise price, exercisable	$ 19
Exercise Price Range Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	200,000
Exercise price, outstanding	$ 1.32
Number of options, exercisable	200,000
Exercise price, exercisable	$ 1.32

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
Schedule of Warrant Activity (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Equity [Abstract]
Warrants outstanding, beginning balance	806,254
Weighted average exercise price, outstanding, beginning balance	$ 12.05
Weighted average remaining contractual life, outstanding, beginning balance	3 years 5 months 15 days	3 years 8 months 15 days
Aggregate intrinsic value, outstanding, beginning balance	$ 106,960
Warrants outstanding, granted
Warrants outstanding, forfeited
Warrants outstanding, exercised	(518,061)
Warrants outstanding, beginning balance	288,193	806,254
Weighted average exercise price, outstanding, beginning balance	$ 30.46	$ 12.05
Aggregate intrinsic value, outstanding, beginning balance	$ 5,400	$ 106,960
Warrants outstanding, exercisable	288,193
Weighted average exercise price, exercisable	$ 30.46
Weighted average remaining contractual life, exercisable	3 years 5 months 15 days
Aggregate intrinsic value, exercisable	$ 5,400

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - $ / shares	Nov. 30, 2023	Aug. 31, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	288,193	806,254
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	261,193
Exercise Price, Outstanding and Exercisable	$ 33.50
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	27,000
Exercise Price, Outstanding and Exercisable	$ 1
Exercise Price Range [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	288,193

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)

3 Months Ended

12 Months Ended

15 Months Ended

Nov. 07, 2023

Nov. 06, 2023

Oct. 12, 2023

Sep. 12, 2023

Jun. 20, 2023

Mar. 21, 2023

Feb. 24, 2023

Feb. 09, 2021

Nov. 30, 2023

Nov. 30, 2022

Aug. 31, 2023

Nov. 30, 2023

Dec. 21, 2023

Sep. 29, 2023

Jul. 26, 2023

Feb. 23, 2023

Dec. 14, 2021

Nov. 17, 2021

Jan. 16, 2018

Sep. 08, 2015

Accumulated Other Comprehensive Income (Loss) [Line Items]

Reverse stock split

1-for-10 reverse stock split

Convertible preferred stock, shares authorized

1,000,000

Convertible preferred stock, par value

$ 0.001

Convertible preferred stock, shares issued

Convertible preferred stock, shares outstanding

Common stock, shares authorized

499,000,000

Common stock, par value

$ 0.001

Common stock, shares issued

17,291,192

15,759,325

17,291,192

Common stock, shares outstanding

17,291,192

15,759,325

17,291,192

Proceeds of warrants

$ 240,400

Promissory note issued

$ 1,875,000

Debt conversion, converted instrument, shares issued

27,973

Common stock to be issued

44,443

$ 1,217,293

$ 44,443

Stock option expense

$ 60,887

Unamortized stock option expense

2015 Incentive Compensation Plan [Member] | Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of common stock shares authorized

50,000

2018 Incentiven Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of common stock shares authorized

100,000

Number of shares available for future grant

86,490

2021 Equity Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of common stock shares authorized

450,000

Number of shares available for future grant

75,463

Term of award description

the maximum aggregate
number of shares that may be issued under the 2021 Plan may be cumulatively increased on January 1, 2022 and on each subsequent January
1 through and including January 1, 2024, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock
issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company
chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan, effective January 1, 2022 and January 1, 2023.
As of November 30, 2023, the 2021 Plan had 75,463 shares available for award; however, the Company does not intend to issue any additional
grants under the 2021 Plan

Two Thousand And Twenty Three Equity Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of common stock shares authorized

2,500,000

Taddeo Hovius Physiotherapy Professional Corp [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issued for acquisition, shares

17,375

Common stock to be issued

$ 44,443

Board of Directors Chairman [Member] | Two Thousand And Twenty Three Equity Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of common stock shares authorized

2,500,000

Share Exchange Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Sep. 05, 2023

Mast Hill Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Units issued for cash, net of offering costs

1,772,045

74,167

Number of restricted shares

95,500

53,567

Shares issuance date

Sep. 18, 2023

Promissory note issued

$ 3,500,000

$ 445,000

$ 573,000

Interest

$ 6,028

Debt conversion, converted instrument, shares issued

522,777

Consulting Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Oct. 12, 2023

Sep. 18, 2023

Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

519,845

Shares issuance date

Sep. 21, 2023

Promissory note issued

$ 573,000

573,000

Interest

$ 4,521

4,521

Debt conversion, converted instrument, shares issued

577,521

First Fire Warrant Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

53,532

Promissory note issued

$ 573,000

Consulting Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Oct. 18, 2023

Mast Hil lSecurities Warrant Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

138,703

Shares issuance date

Oct. 23, 2023

Promissory note issued

445,000

Consulting Agreement Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

75,000

Shares issuance date

Nov. 08, 2023

Excutive Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

30,675

Shares issuance date

Nov. 21, 2023

Excutive Agreement One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

18,405

Shares issuance date

Nov. 21, 2023

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Units issued for cash, net of offering costs

80,200

Warrants and rights outstanding term

3 years

Proceeds of warrants

$ 80,200

Promissory note issued

$ 5,257,466

Warrant [Member] | Mast Hill Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Promissory note issued

77,856

86,327

Warrant One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Units issued for cash, net of offering costs

160,200

Warrants and rights outstanding term

5 years

Proceeds of warrants

$ 160,200

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Units issued for cash, net of offering costs

400,000

Debt conversion, converted instrument, shares issued

3,786,454

Common Stock [Member] | Mast Hill Securities Purchase Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Promissory note issued

$ 74,793

$ 82,963

Common Stock [Member] | Consulting Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares issuance date

Oct. 03, 2023

Common Stock [Member] | Share Exchange Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Number of restricted shares

73,767

Shares issuance date

Oct. 09, 2023

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	3 Months Ended
Commitments and Contingencies (Details Narrative)	Nov. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Other expenses	$ 652,174

Schedule of Segment Reporting I

Schedule of Segment Reporting Information (Details) - USD ($)	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Aug. 31, 2023	Aug. 31, 2022
Segment Reporting Information [Line Items]
Sales	$ 3,891,218	$ 3,419,280
Gross profit	1,944,018	1,739,533
Income (loss) from operations	(3,317,637)	(2,241,960)
Depreciation and amortization	572,404	586,166
Capital expenditures
Interest expenses	143,374	167,243
Net loss	(4,660,723)	(3,936,736)
Total assets	37,244,384		$ 35,563,047
Accounts receivable	2,636,174		1,467,028
Intangible assets	15,704,218		16,218,539
Goodwill	7,554,779		7,582,483	$ 7,825,844
Healthcare Services [Member]
Segment Reporting Information [Line Items]
Sales	2,044,510	2,021,213
Gross profit	676,416	784,031
Income (loss) from operations	(80,327)	(151,691)
Depreciation and amortization	30,035	28,968
Capital expenditures
Interest expenses	20,532	36,303
Net loss	(98,640)	(185,713)
Total assets	5,002,855		5,158,851
Accounts receivable	672,841		697,440
Intangible assets	111,172		120,163
Goodwill	518,918		520,821
Product Manufacturing and Development [Member]
Segment Reporting Information [Line Items]
Sales	1,768,458	790,478
Gross profit	1,189,352	347,914
Income (loss) from operations	108,702	(554,842)
Depreciation and amortization	262,927	309,042
Capital expenditures
Interest expenses	462	2,464
Net loss	48,883	(578,576)
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Sales	78,250	607,589
Gross profit	78,250	607,588
Income (loss) from operations	(3,346,012)	(1,535,427)
Depreciation and amortization	279,442	248,156
Capital expenditures
Interest expenses	122,380	128,476
Net loss	(4,610,966)	$ (3,172,447)
Total assets	13,493,054		12,410,544
Accounts receivable	94,946		4,200
Intangible assets	12,000,621		12,280,063
Goodwill
Product Sales [Member]
Segment Reporting Information [Line Items]
Total assets	18,748,475		17,993,652
Accounts receivable	1,868,387		765,388
Intangible assets	3,592,425		3,818,313
Goodwill	$ 7,035,861		$ 7,061,662

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

3 Months Ended

12 Months Ended

Jan. 16, 2024

Dec. 21, 2023

Dec. 18, 2023

Dec. 12, 2023

Nov. 21, 2023

Nov. 07, 2023

Sep. 12, 2023

Jun. 20, 2023

Nov. 30, 2023

Nov. 30, 2022

Aug. 31, 2023

Sep. 18, 2023

Feb. 23, 2023

Nov. 17, 2021

Subsequent Event [Line Items]

Debt face amount

$ 1,875,000

Debt conversion, converted instrument, shares issued

27,973

Debt conversion, rate

$ 0.001

Promissory note paid in full

$ 183,100

Common Stock [Member]

Subsequent Event [Line Items]

Debt conversion, converted instrument, shares issued

3,786,454

Units issued for cash, net of offering costs, shares

400,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Amount of debt converted

$ 454,071

Debt conversion, converted instrument, shares issued

457,128

Debt conversion, rate

$ 0.99331

Promissory note paid in full

$ 445,000

Shares issued, price per share

$ 0.78

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Units issued for cash, net of offering costs, shares

200,000

Ophir Agreement [Member]

Subsequent Event [Line Items]

Security deposit

$ 25,000

Repayments of related party

60,000,000

Repayments of related party excluding deposit

$ 59,975,000

Mast Hill Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Debt face amount

$ 445,000

$ 3,500,000

$ 445,000

$ 573,000

Debt conversion, converted instrument, shares issued

522,777

Units issued for cash, net of offering costs, shares

1,772,045

74,167

Mast Hill Securities Purchase Agreement [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Debt face amount

$ 74,793

$ 82,963

Mast Hill Securities Purchase Agreement [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Convertible notes interest

$ 104,712

FirstFire Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Debt face amount

$ 277,778

Units issued for cash, net of offering costs, shares

480,156

FirstFire Securities Purchase Agreement [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Convertible notes interest

$ 8,333